Comparison of the ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System With a Drug- Eluting Metal Stent (XienceTM) in Acute ST-Elevation Myocardial Infarction

Trial Profile

Comparison of the ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System With a Drug- Eluting Metal Stent (XienceTM) in Acute ST-Elevation Myocardial Infarction

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Myocardial infarction; Thrombosis; Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms TROFI-II
  • Most Recent Events

    • 10 Aug 2017 Planned End Date changed from 1 Sep 2017 to 1 Oct 2017.
    • 23 Sep 2015 Results published in the European Heart Journal
    • 12 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top